MX2021001550A - Inhibidores de transglutaminasa 2 (tg2). - Google Patents
Inhibidores de transglutaminasa 2 (tg2).Info
- Publication number
- MX2021001550A MX2021001550A MX2021001550A MX2021001550A MX2021001550A MX 2021001550 A MX2021001550 A MX 2021001550A MX 2021001550 A MX2021001550 A MX 2021001550A MX 2021001550 A MX2021001550 A MX 2021001550A MX 2021001550 A MX2021001550 A MX 2021001550A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitors
- transglutaminase
- compounds
- inhibition
- benefit
- Prior art date
Links
- 108700039882 Protein Glutamine gamma Glutamyltransferase 2 Proteins 0.000 title abstract 5
- 102100038095 Protein-glutamine gamma-glutamyltransferase 2 Human genes 0.000 title abstract 5
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862717697P | 2018-08-10 | 2018-08-10 | |
| US201962845229P | 2019-05-08 | 2019-05-08 | |
| PCT/US2019/045827 WO2020033784A1 (en) | 2018-08-10 | 2019-08-09 | Transglutaminase 2 (tg2) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021001550A true MX2021001550A (es) | 2021-07-15 |
Family
ID=69415167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021001550A MX2021001550A (es) | 2018-08-10 | 2019-08-09 | Inhibidores de transglutaminasa 2 (tg2). |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US12152026B2 (enExample) |
| EP (2) | EP3833348B1 (enExample) |
| JP (1) | JP7433315B2 (enExample) |
| KR (1) | KR102904276B1 (enExample) |
| CN (1) | CN112789040A (enExample) |
| AU (1) | AU2019318543B2 (enExample) |
| BR (1) | BR112021002532A2 (enExample) |
| CL (1) | CL2021000328A1 (enExample) |
| CO (1) | CO2021001472A2 (enExample) |
| CY (1) | CY1126147T1 (enExample) |
| DK (1) | DK3833348T3 (enExample) |
| ES (2) | ES3017786T3 (enExample) |
| FI (1) | FI3833348T3 (enExample) |
| HR (1) | HRP20230798T1 (enExample) |
| HU (1) | HUE062140T2 (enExample) |
| IL (1) | IL280719B2 (enExample) |
| LT (1) | LT3833348T (enExample) |
| MX (1) | MX2021001550A (enExample) |
| MY (1) | MY205622A (enExample) |
| PH (1) | PH12021500008A1 (enExample) |
| PL (1) | PL3833348T3 (enExample) |
| PT (1) | PT3833348T (enExample) |
| RS (1) | RS64464B1 (enExample) |
| SG (1) | SG11202100736PA (enExample) |
| SI (1) | SI3833348T1 (enExample) |
| SM (1) | SMT202300186T1 (enExample) |
| TW (1) | TWI825144B (enExample) |
| UY (1) | UY38333A (enExample) |
| WO (1) | WO2020033784A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11466017B2 (en) | 2011-03-10 | 2022-10-11 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
| WO2017210134A1 (en) | 2016-05-31 | 2017-12-07 | Board Of Regents, University Of Texas System | Heterocyclic inhibitors of ptpn11 |
| KR102611661B1 (ko) | 2018-05-02 | 2023-12-08 | 나비레 파르마, 인코퍼레이티드 | Ptpn11의 치환된 헤테로사이클릭 억제제 |
| US12157746B2 (en) | 2018-06-05 | 2024-12-03 | Hoffmann-La Roche Inc. | Tetrahydro-1H-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease |
| PL3833670T3 (pl) | 2018-08-10 | 2024-08-19 | Navire Pharma, Inc. | Pochodne 6-(4-amino-3-metylo-2-oksa-8-azaspiro[4.5]dekan-8-ylo)-3-(2,3-dichlorofenylo)-2-metylopirymidyn-4(3h)-onu oraz powiązane związki jako inhibitory ptpn11 (shp2) do leczenia raka |
| TWI825144B (zh) * | 2018-08-10 | 2023-12-11 | 美商思達利醫藥公司 | 第二型轉麩醯胺酸酶(tg2)抑制劑 |
| WO2020227549A1 (en) | 2019-05-08 | 2020-11-12 | Aligos Therapeutics, Inc. | MODULATORS OF THR-β AND METHODS OF USE THEREOF |
| IL309476A (en) * | 2021-06-30 | 2024-02-01 | Zedira Gmbh | Transglutaminase inhibitors |
| DK4192812T3 (da) * | 2021-06-30 | 2024-09-16 | Zedira Gmbh | Transglutaminase-inhibitorer |
| WO2023090479A1 (ko) * | 2021-11-18 | 2023-05-25 | 주식회사 엠디바이오팜 | 신규한 트랜스글루타미나제 2 억제제 및 이의 용도 |
| CN115611760A (zh) * | 2022-10-13 | 2023-01-17 | 天津药明康德新药开发有限公司 | 一种适合规模化生产(s)-2-氨基-5-炔基己酸的化学合成方法 |
| EP4653420A1 (en) * | 2023-01-17 | 2025-11-26 | Shenyang Haisco Pharmaceutical Co., Ltd. | Method for preparing chiral amino alcohol pharmaceutical intermediates |
| CN116891413A (zh) * | 2023-06-06 | 2023-10-17 | 山东东岳高分子材料有限公司 | 一种连续化制备2,4,5-三氟苯胺的方法 |
| CN117024254B (zh) * | 2023-08-10 | 2025-09-09 | 浙江大学衢州研究院 | 一种多氟苯酚的合成方法 |
| WO2025153465A1 (en) | 2024-01-15 | 2025-07-24 | UCB Biopharma SRL | Method for the treatment of fibrotic-related disorder associated to ibd |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5021440A (en) | 1989-07-31 | 1991-06-04 | Merck & Co., Inc. | Imidazole compounds and their use as transglutaminase inhibitors |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| GB9509271D0 (en) | 1995-05-05 | 1995-06-28 | Biopharm Res & Dev Ltd | Blood clot stabilisation inhibitors |
| US7579313B2 (en) | 2003-11-18 | 2009-08-25 | The Board Of Trustees Of The Leland Stanford Junior University | Transglutaminase inhibitors and methods of use thereof |
| US20060183759A1 (en) | 2004-12-03 | 2006-08-17 | Stein Ross L | Tissue transglutaminase inhibitors |
| DE102006052755A1 (de) | 2006-11-08 | 2008-05-15 | N-Zyme Biotec Gmbh | Michaelsysteme als Transglutaminaseinhibitoren |
| SI2558577T1 (sl) | 2010-04-16 | 2019-05-31 | Nuevolution A/S | Bifunkcionalni kompleksi in metode za pripravo in uporabo takšnih kompleksov |
| WO2011151395A2 (en) | 2010-06-02 | 2011-12-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Transglutaminase 2 inhibitors for use in the prevention or treatment of rapidly progressive glomerulonephritis |
| WO2012078519A2 (en) | 2010-12-06 | 2012-06-14 | Numerate, Inc. | 3-acylidene-2-oxoindole derivatives for inhibition of transglutaminase 2 |
| US8889716B2 (en) | 2011-05-10 | 2014-11-18 | Chdi Foundation, Inc. | Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof |
| WO2013093484A1 (en) | 2011-12-21 | 2013-06-27 | Ono Pharmaceutical Co., Ltd. | Pyridinone and pyrimidinone derivatives as factor xia inhibitors |
| EP2687511A1 (de) * | 2012-07-17 | 2014-01-22 | Zedira GmbH | Pyridinonderivate als Gewebetransglutaminaseinhibitoren |
| TW201418198A (zh) | 2012-09-21 | 2014-05-16 | Chdi Foundation Inc | 轉麩醯胺酸酶ｔｇ２抑制劑，醫藥組成物及其使用方法 |
| KR101548789B1 (ko) | 2012-12-21 | 2015-09-01 | 주식회사 엘지화학 | 케이블형 이차전지 및 이의 제조 방법 |
| CN107231804B (zh) | 2015-01-14 | 2019-11-26 | 百时美施贵宝公司 | 亚杂芳基桥连苯并二氮杂*二聚体、其缀合物及制备和使用方法 |
| EP3342779A1 (en) | 2016-12-27 | 2018-07-04 | Zedira GmbH | Inhibitors of transglutaminases |
| TWI825144B (zh) * | 2018-08-10 | 2023-12-11 | 美商思達利醫藥公司 | 第二型轉麩醯胺酸酶(tg2)抑制劑 |
-
2019
- 2019-08-08 TW TW108128272A patent/TWI825144B/zh active
- 2019-08-09 FI FIEP19846381.2T patent/FI3833348T3/fi active
- 2019-08-09 HR HRP20230798TT patent/HRP20230798T1/hr unknown
- 2019-08-09 ES ES23174889T patent/ES3017786T3/es active Active
- 2019-08-09 EP EP19846381.2A patent/EP3833348B1/en active Active
- 2019-08-09 CN CN201980065467.5A patent/CN112789040A/zh active Pending
- 2019-08-09 WO PCT/US2019/045827 patent/WO2020033784A1/en not_active Ceased
- 2019-08-09 LT LTEPPCT/US2019/045827T patent/LT3833348T/lt unknown
- 2019-08-09 UY UY0001038333A patent/UY38333A/es not_active Application Discontinuation
- 2019-08-09 US US17/267,110 patent/US12152026B2/en active Active
- 2019-08-09 MX MX2021001550A patent/MX2021001550A/es unknown
- 2019-08-09 KR KR1020217006925A patent/KR102904276B1/ko active Active
- 2019-08-09 AU AU2019318543A patent/AU2019318543B2/en active Active
- 2019-08-09 JP JP2021531468A patent/JP7433315B2/ja active Active
- 2019-08-09 ES ES19846381T patent/ES2947438T3/es active Active
- 2019-08-09 SG SG11202100736PA patent/SG11202100736PA/en unknown
- 2019-08-09 EP EP23174889.8A patent/EP4219460B1/en active Active
- 2019-08-09 RS RS20230613A patent/RS64464B1/sr unknown
- 2019-08-09 IL IL280719A patent/IL280719B2/en unknown
- 2019-08-09 MY MYPI2021000686A patent/MY205622A/en unknown
- 2019-08-09 BR BR112021002532-4A patent/BR112021002532A2/pt unknown
- 2019-08-09 DK DK19846381.2T patent/DK3833348T3/da active
- 2019-08-09 SM SM20230186T patent/SMT202300186T1/it unknown
- 2019-08-09 HU HUE19846381A patent/HUE062140T2/hu unknown
- 2019-08-09 PT PT198463812T patent/PT3833348T/pt unknown
- 2019-08-09 SI SI201930559T patent/SI3833348T1/sl unknown
- 2019-08-09 PL PL19846381.2T patent/PL3833348T3/pl unknown
-
2021
- 2021-01-27 PH PH12021500008A patent/PH12021500008A1/en unknown
- 2021-02-08 CL CL2021000328A patent/CL2021000328A1/es unknown
- 2021-02-09 CO CONC2021/0001472A patent/CO2021001472A2/es unknown
-
2022
- 2022-05-20 US US17/749,335 patent/US11548892B1/en active Active
-
2023
- 2023-08-04 CY CY20231100392T patent/CY1126147T1/el unknown
-
2024
- 2024-09-06 US US18/826,431 patent/US20250011324A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021500008A1 (en) | Transglutaminase 2 (tg2) inhibitors | |
| PH12022550399A1 (en) | MTA-Cooperative PRMT5 Inhibitors | |
| MX2025003987A (es) | Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos | |
| MX2021014441A (es) | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. | |
| MY205416A (en) | Tyk2 inhibitors and uses thereof | |
| PH12022551013A1 (en) | Pyridazinones as parp7 inhibitors | |
| PH12020551244A1 (en) | Pd-1/pd-l1 inhibitors | |
| MX2020007797A (es) | Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos. | |
| JOP20180039A1 (ar) | مثبطات pd-1/pd-l1 | |
| WO2020252229A3 (en) | Inhibitors of sarm1 | |
| PH12020550792A1 (en) | Compounds useful for inhibiting cdk7 | |
| EP3848370A3 (en) | Tyk2 inhibitors and uses thereof | |
| MY196836A (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| EP4327809A3 (en) | Tyk2 inhibitors and uses thereof | |
| MX2017012738A (es) | Inhibidores de indolamina 2.3-dioxigenasa (ido) para el tratamiento de cancer. | |
| JOP20210158A1 (ar) | مُعَدِّلات التعبير الجيني عن hsd17b13 | |
| EP4600247A3 (en) | Pd-1/pd-l1 inhibitors | |
| MX2020011344A (es) | Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios. | |
| MX2019011506A (es) | Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer. | |
| MX2017015923A (es) | Inhibidores de indolamina-2,3-dioxigenasa (ido). | |
| ZA202310843B (en) | Chromene derivatives as inhibitors of tcr-nck interaction | |
| EA201691549A1 (ru) | Ариллактамные ингибиторы киназы | |
| MY201291A (en) | Aminothiazole compounds as protein kinase inhibitors | |
| MX2019009200A (es) | Composiciones y métodos para inhibir el reticulón 4. | |
| AU2020378127A8 (en) | Compounds as CD73 inhibitors |